Mok TS, Kim D, Wu Y, et al. Overall Survival (OS) for First-Line Crizotinib Versus Chemotherapy in ALK+ Lung Cancer: Updated Results from PROFILE 1014. ESMO 2017, abstract LBA50.
Incidentie en overleving van maligne extracraniële kiemceltumoren in Nederland: 1990-2018
mei 2024